Drugs / D-2570
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07715175 | Aug → Nov 2026 expected | impaired renal function disease | InventisBio Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07715149 | Jul → Oct 2026 expected | — | InventisBio Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT07411742 | Mar 2026 overdue | — | InventisBio Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07270783 | Dec 2025 → Jun 2026 overdue | — | InventisBio Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07275775 | Aug 2024 → Jun 2025 | — | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT07625891 | Jun 2026 → Nov 2027 expected | vitiligo | InventisBio Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07311200 | Feb 2026 → Aug 2028 expected | systemic lupus erythematosus | InventisBio Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07315061 | Jan 2026 → Aug 2027 expected | psoriatic arthritis | InventisBio Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07035041 | May 2025 → Jul 2026 overdue | ulcerative colitis | InventisBio Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06278350 | Jan → Nov 2024 | psoriasis | InventisBio Co., Ltd | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT07326813 | Jan 2026 → Jul 2027 expected | psoriasis | InventisBio Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07130604 | Sep 2025 → Jul 2027 expected | psoriasis | InventisBio Co., Ltd | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07489885 Comparator | Jun 2026 → Aug 2027 expected | psoriasis | InventisBio Co., Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-12-03 | InventisBio Co., Ltd | Results InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis inventisbio.com ↗
InventisBio Co., Ltd. today announced promising results from a Phase 2 clinical trial of D-2570, an oral selective inhibitor of the TYK2 kinase, in patients with moderate to severe plaque psoriasis. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-12-03 | InventisBio Co., Ltd | InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis inventisbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D-2570 | “BACKGROUND: D-2570, a TYK2 inhibitor, is currently being developed for autoimmune diseases including psoriasis and ulcerative colitis.” PMID 40967307 ↗ Sep 202512“A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis” NCT07035041 ↗ |
| Action | Inhibit | “D-2570, a TYK2 inhibitor” PMID 40967307 ↗ Sep 2025 |
| Route | Oral | “D-2570 is being developed as a potential oral therapeutic drug for patients with psoriasis, ulcerative colitis, SLE, and other conditions.” NCT07275775 ↗ |
| Target | TYK2 | “D-2570, a TYK2 inhibitor” PMID 40967307 ↗ Sep 2025 |